Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 known ✓ | Q12809 | 2/20 | 0.98 |
| ▸ | PTPN11 | Q06124 | 20/20 | 0.98 |
| ▸ | MAPK3 | P27361 | 1/20 | 0.98 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.98 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL29479127 | 1.00 | PTPN11 (0.98) | PTPN11KCNH2MAPK3MAPK1 | |
| Hydrochloric Acid SCHEMBL29828013 | 1.00 | PTPN11 (0.98) | PTPN11KCNH2MAPK3MAPK1 | |
| Hydrochloric Acid SCHEMBL29024442 | 1.00 | PTPN11 (0.98) | PTPN11KCNH2MAPK3MAPK1 | |
| SCHEMBL16914284 | 0.99 | PTPN11 (1.00) | PTPN11KCNH2MAPK3MAPK1 | |
| SCHEMBL29352400 | 0.99 | PTPN11 (1.00) | PTPN11KCNH2MAPK3MAPK1 | |
| SCHEMBL26247011 | 0.91 | PTPN11 (0.85) | PTPN11KCNH2MAPK3MAPK1 | |
| SCHEMBL26015655 | 0.89 | PTPN11 (0.82) | PTPN11KCNH2MAPK3MAPK1 | |
| SCHEMBL30295870 | 0.88 | PTPN11 (0.80) | PTPN11KCNH2MAPK3MAPK1 | |
| SCHEMBL19785300 | 0.88 | PTPN11 (0.80) | PTPN11KCNH2MAPK3MAPK1 | |
| SCHEMBL25485425 | 0.87 | PTPN11 (0.78) | PTPN11KCNH2MAPK3MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240423984-A1 | COMBINATION THERAPIES OF KRAS G12D INHIBITORS WITH SHP-2 INHIBITORS | MIRATI THERAPEUTICS, INC | 2024-12-26 | — | — | US | claimed |
| US-20220079947-A1 | COMBINATION THERAPIES | Mirati Therapeutics, Inc. | 2022-03-17 | — | — | US | claimed |
| US-20210113659-A1 | ENGINEERED THERAPEUTIC TO ENHANCE CYTOTOXIC ACTIVITY AND PHAGOCYTOSIS IN TUMOR ASSOCIATED MACROPHAGES | UNIVERSITY OF MASSACHUSETTS | 2021-04-22 | — | — | US | claimed |
| US-20250340548-A1 | KRAS G12C INHIBITORS | FRONTIER MEDICINES CORP (US) | 2025-11-06 | — | — | US | disclosed |
| US-12377101-B2 | Combination therapies | Mirati Therapeutics, Inc. (US) | 2025-08-05 | — | — | US | disclosed |
| WO-2025106901-A1 | COMBINATION CANCER THERAPIES WITH A KRAS MODULATOR AND AN RTK-MAPK PATHWAY INHIBITOR | QUANTA THERAPEUTICS, INC. (US) | 2025-05-22 | — | — | WO | disclosed |
| US-12291539-B2 | KRAS G12C inhibitors | FRONTIER MEDICINES CORPORATION (US) | 2025-05-06 | — | — | US | disclosed |
| US-20250129103-A1 | METHODS FOR TREATMENT OF CANCER | FRONTIER MEDICINES CORPORATION | 2025-04-24 | — | — | US | disclosed |
| US-20250019387-A1 | KRAS G12C INHIBITORS | FRONTIER MEDICINES CORPORATION | 2025-01-16 | — | — | US | disclosed |
| US-20240423984-A1 | COMBINATION THERAPIES OF KRAS G12D INHIBITORS WITH SHP-2 INHIBITORS | MIRATI THERAPEUTICS, INC | 2024-12-26 | — | — | US | disclosed |
| US-20240417412-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | AMGEN INC. (US) | 2024-12-19 | — | — | US | disclosed |
| CN-117835976-A | Heterocyclic compounds and methods of use | 安进公司 | 2024-04-05 | — | — | CN | disclosed |
| CN-117651700-A | 2-aminobenzothiazole compounds and methods of use | 安进公司 | 2024-03-05 | — | — | CN | disclosed |
| CN-117561063-A | Heterocyclic compounds and methods of use | 安进公司 | 2024-02-13 | — | — | CN | disclosed |
| WO-2023150394-A1 | METHODS FOR TREATMENT OF CANCER | FRONTIER MEDICINES CORPORATION (US) | 2023-08-10 | — | — | WO | disclosed |
| WO-2023081840-A1 | KRAS G12C INHIBITORS | FRONTIER MEDICINES CORPORATION (US) | 2023-05-11 | — | — | WO | disclosed |
| US-20220079947-A1 | COMBINATION THERAPIES | Mirati Therapeutics, Inc. | 2022-03-17 | — | — | US | disclosed |
| EP-3890716-A1 | COMBINATION THERAPIES | Mirati Therapeutics, Inc. (US) | 2021-10-13 | — | — | EP | disclosed |
| US-20210113659-A1 | ENGINEERED THERAPEUTIC TO ENHANCE CYTOTOXIC ACTIVITY AND PHAGOCYTOSIS IN TUMOR ASSOCIATED MACROPHAGES | UNIVERSITY OF MASSACHUSETTS | 2021-04-22 | — | — | US | disclosed |
| WO-2020118066-A1 | COMBINATION THERAPIES | Mirati Therapeutics, Inc. (US) | 2020-06-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240423984-A1 | COMBINATION THERAPIES OF KRAS G12D INHIBITORS WITH SHP-2 INHIBITORS | KRAS, NRAS, SHPRH | KCNH2 4609/4885PTPN11 24/4885MAPK3 765/4885 |
| US-20240417412-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | KRAS, NRAS, HRAS | KCNH2 4325/4885PTPN11 551/4885MAPK3 554/4885 |
| US-12291539-B2 | KRAS G12C inhibitors | KRAS, NRAS, HRAS | KCNH2 4645/4885PTPN11 583/4885MAPK3 525/4885 |
| US-20250129103-A1 | METHODS FOR TREATMENT OF CANCER | KRAS, HRAS, TP53 | KCNH2 4760/4885PTPN11 1658/4885MAPK3 2082/4885 |
| US-20250340548-A1 | KRAS G12C INHIBITORS | KRAS, NRAS, HRAS | KCNH2 4645/4885PTPN11 583/4885MAPK3 525/4885 |
| US-20220079947-A1 | COMBINATION THERAPIES | KRAS, NRAS, HRAS | KCNH2 4389/4885PTPN11 9/4885MAPK3 1039/4885 |
| US-12377101-B2 | Combination therapies | KRAS, NRAS, HRAS | KCNH2 4389/4885PTPN11 9/4885MAPK3 1039/4885 |
| US-20250019387-A1 | KRAS G12C INHIBITORS | KRAS, NRAS, HRAS | KCNH2 4645/4885PTPN11 583/4885MAPK3 525/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.